Daratumumab Induces CD38 Internalization and Impairs Myeloma Cell Adhesion

OncoImmunology - United States
doi 10.1080/2162402x.2018.1486948
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

The Therapeutic Human CD38 Antibody Daratumumab Improves the Anti-Myeloma Effect of Newly Emerging Multi-Drug Therapies

Blood Cancer Journal
OncologyHematology
2011English

CD38: From Positive to Negative Expression After Daratumumab Treatment

Cureus
2020English

Daratumumab in Untreated Newly Diagnosed Multiple Myeloma

Therapeutic Advances in Hematology
Hematology
2019English

CD38-driven Mitochondrial Trafficking Promotes Bioenergetic Plasticity in Multiple Myeloma

Cancer Research
Cancer ResearchOncology
2019English

CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon

Clinical Cancer Research
Cancer ResearchOncology
2015English

Cost-Effectiveness Analysis of Daratumumab, Lenalidomide, and Dexamethasone (DRD) and Daratumumab, Bortezomib, and Dexamethasone (DVD) Versus Standard of Care in Relapsed or Refractory Multiple Myeloma (RRMM)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

CD38 Negative Anaplastic Plasma Cell Myeloma With (14;16) Translocation: A Diagnostic Dilemma for Highly Aggressive Neoplasm: Case Report

Journal of Hematopathology
Forensic MedicinePathologyHematologyHistology
2019English

Disseminated Cryptococcosis in a Patient With Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone

Internal Medicine
Internal MedicineMedicine
2019English

Staurosporine Induces Endothelial Cell Apoptosis via Focal Adhesion Kinase Dephosphorylation and Focal Adhesion Disassembly Independent of Focal Adhesion Kinase Proteolysis

Biochemical Journal
BiochemistryCell BiologyMolecular Biology
2002English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy